Traders Buy Large Volume of PDS Biotechnology Call Options (NASDAQ:PDSB)

PDS Biotechnology Corporation (NASDAQ:PDSB) saw unusually large options trading on Tuesday. Investors purchased 1,957 call options on the company. This is an increase of 1,154% compared to the average volume of 156 call options.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PDSB. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a report on Wednesday, August 26th. Finally, Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, PDS Biotechnology currently has an average rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Stock Up 49.1%

NASDAQ PDSB traded up $0.11 during trading on Tuesday, hitting $0.33. 332,200,471 shares of the company traded hands, compared to its average volume of 2,553,967. PDS Biotechnology has a 12 month low of $0.20 and a 12 month high of $1.55. The business has a fifty day simple moving average of $0.54 and a 200 day simple moving average of $0.79. The company has a market capitalization of $18.36 million, a P/E ratio of -0.51 and a beta of 1.46. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). As a group, sell-side analysts predict that PDS Biotechnology will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in PDS Biotechnology during the 2nd quarter worth $535,000. Bank of New York Mellon Corp acquired a new stake in shares of PDS Biotechnology in the second quarter valued at about $60,000. Renaissance Technologies LLC increased its stake in shares of PDS Biotechnology by 25.0% in the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after purchasing an additional 44,100 shares during the period. Virtu Financial LLC bought a new position in shares of PDS Biotechnology in the fourth quarter worth about $25,000. Finally, Armistice Capital LLC acquired a new position in shares of PDS Biotechnology during the 4th quarter worth about $2,182,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.